MARRS study milestone positions Perfuze for U.S. expansion
Perfuze has completed enrollment in its MARRS trial, evaluating the Millipede 088 aspiration catheter for large vessel occlusion (LVO) stroke treatment. Over 180 patients were enrolled in the U.S. and Europe ahead of schedule.
The company aims to use trial data to support an FDA submission for expanded stroke thrombectomy use. Millipede 088 is designed for rapid, complete clot removal, offering a simpler, more effective treatment approach.
Additionally, Joe Rotger joins as EVP of sales, bringing neurovascular leadership experience from Stryker and Boston Scientific.
Follow MEDWIRE.AI for stroke care innovation updates.
